Skip to content
‹ Back to IndustriesSciences

UCB commits to Veeva Vault CRM for unified engagement

UCB has committed to Veeva Vault CRM, which Veeva's release presents as an agentic CRM platform to drive unified engagement worldwide. Executives from both companies describe it as a foundation for commercial execution, while the AI claims, including the Agentic Call Report, come from Veeva's product description. No go-live date or financial terms were given.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · UcbVeeva SystemsVeeva Vault CrmLife Sciences Crm
Share
UCB commits to Veeva Vault CRM for unified engagement

Key takeaways

01

The executive statements focus on Vault CRM as a foundation. The AI pitch, including the Agentic Call Report, comes from Veeva’s product description.

02

Veeva says the Agentic Call Report turns field call records into "Commercial Evidence" about treatment barriers that went unseen before. If that works, call-report data becomes something UCB can analyze.

03

Neither company disclosed a go-live date or financial terms. The first rollout milestone UCB names will be the signal that the move is actually happening.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

UCB has committed to Veeva Vault CRM, which Veeva Systems calls the agentic engagement platform for life sciences. The release's subtitle reads "Agentic CRM platform to drive unified engagement worldwide."

Chris Moore, president of Veeva Europe, called Vault CRM a stable, scalable and future-ready foundation for UCB's commercial strategy.

Turning call reports into evidence

Veeva describes Vault CRM as an agentic engagement platform for life sciences, with AI built for the industry to speed up product launches and improve customer experience.

The release names one specific feature: the Agentic Call Report. Veeva says it creates what it calls Commercial Evidence, meant to surface treatment barriers that were previously hidden.

If the feature does what Veeva describes, the value of a call report moves from what one rep wrote down to what thousands of reports reveal when read together.

Foundation talk, AI in the product copy

Read the two executive statements again. Erckens talks about a foundation for commercial execution. Moore's words are stable, scalable and future-ready. Neither mentions AI. The agentic language, the launch acceleration and the Commercial Evidence claim all come from Veeva's description of the product.

Both executives talked about foundations. The AI pitch lives in Veeva's product copy.

Both executives talked about foundations. The AI pitch lives in Veeva's product copy.

Reading too much into the AI angle has a real limit. Everything Vault CRM is said to do in this announcement is a capability Veeva has announced, not a result UCB has seen. The release reports a commitment, not a deployment. For a buyer comparing platforms, the safer reading is that UCB chose a CRM base it expects to grow with. Whether the Agentic Call Report changes how its teams work is a question for later.

An open schedule

Erckens's wording suggests UCB is going deeper with a vendor it already works with, rather than bringing in a new one. Investing.com noted that the release gave no financial terms and no implementation timeline.

That leaves two things to watch. The first is a go-live date or first-market rollout from UCB, which would show how quickly a worldwide migration is moving. The second is whether UCB ever reports what the Agentic Call Report produced in practice. That would be the first evidence from a customer, not a vendor, that call reports can show where treatment stalls.

Featured companies

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Why ISPE put peptide and oligo facility design in one guide

Why ISPE put peptide and oligo facility design in one guide

ISPE's new Baseline Guide covers oligonucleotide and peptide facility design in one document, says Jim Love of CRB. It pairs a GMP survey of existing plants with a sustainability outlook and a piping safety framework for scale-up, while FDA's oligonucleotide guidances under dockets opened in 2022 and 2024 remain the regulator's own reference.

  • 01Peptide plants inherited API chemistry thinking and oligo plants biotech thinking; ISPE’s guide puts both modalities in one facility document with both inheritances.
  • 02The guide has three parts: a GMP survey of existing oligo and peptide plants, a forecast of how sustainability and scale will change the processes, and a safety framework for connective piping and equipment.
  • 03FDA keeps its own oligonucleotide-specific guidances under dockets opened in 2022 and 2024, so the ISPE guide works as an industry consensus alongside regulation rather than in place of it.

Nov 5, 2026

Collagen builder Astrion outdrew AstraGin at NuLiv's Bangkok booth

Collagen builder Astrion outdrew AstraGin at NuLiv's Bangkok booth

NuLiv Science says Astrion, its collagen-building ingredient, drew more interest than AstraGin at Vitafoods Asia 2026 in Bangkok, held September 2 to 4. Brands also asked for probiotic strains for pet weight loss, children, and women's health. New trials for AstraGin in Nutrients and Senactiv provide updated evidence for these distinct ingredients.

  • 01At Vitafoods Asia 2026 in Bangkok, Astrion drew more booth interest than AstraGin, NuLiv’s absorption flagship.
  • 02NuLiv says probiotic requests are now split by pet, child and life stage, and the show preview lists strains for women’s health, emotional wellbeing and the gut-muscle axis.
  • 03A newly published crossover trial in Nutrients found AstraGin raised branched-chain amino acid absorption and grip strength in adults aged 60 to 80.

Nov 5, 2026

Astrion drew more interest than AstraGin at NuLiv Science's Bangkok booth

Astrion drew more interest than AstraGin at NuLiv Science's Bangkok booth

NuLiv Science reported from Vitafoods Asia 2026 in Bangkok that collagen-building Astrion drew more interest than AstraGin, its absorption ingredient, as collagen and anti-aging products are heavily marketed and sold in almost every store, a company representative said. A 150-person trial published in Cosmetics in June 2025 found oral Astrion raised skin collagen 13.2%. Mordor Intelligence still puts North America at 37.95% of collagen supplement revenue, with Asia-Pacific growing fastest at 11.65%.

  • 01NuLiv Science expected AstraGin to lead in a new market; at Vitafoods Asia 2026 in Bangkok, its collagen-boosting Astrion drew more attention, the company said.
  • 02Oral Astrion raised skin collagen content 13.2% over 12 weeks in a 150-person, placebo-controlled trial published in Cosmetics in June 2025.
  • 03North America held 37.95% of collagen supplement revenue in 2025 while Asia-Pacific grows fastest at 11.65% a year, Mordor Intelligence estimates.

Nov 5, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512